{"entity":{"id":"nct06820463","kind":"trial","name":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,","aka":["AndroMETa-CRC"],"tldr":"A phase 2 trial of Telisotuzumab adizutecan, Fluorouracil, CAPOX in colorectal cancer, run by AbbVie, now recruiting.","summary":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06820463 by AbbVie, with 390 participants planned, started 2025-04-24 and due to reach its primary completion in 2028-03. Interventions recorded: Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06820463","url":"https://clinicaltrials.gov/study/NCT06820463"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["telisotuzumab-adizutecan","fluorouracil","capox","flot","bevacizumab","panitumumab"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06820463","phase":"2","setting":"A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer","sponsor":"AbbVie","participation":[{"nct":"NCT06820463","source":"https://clinicaltrials.gov/study/NCT06820463","fetchedAt":"2026-10-07T16:55:06.589Z","studySha256":"1721e77c23740f8b342889634c20dae5114b17e981443782201408ce980f694e","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-07","leadSponsor":"AbbVie","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":390,"enrolmentType":"ESTIMATED","siteCount":75,"recruitingSiteCount":75,"countries":["Australia","Austria","Brazil","Canada","Czechia","France","Greece","Israel","Italy","Japan","Puerto Rico","Spain","Taiwan","United Kingdom","United States"]}],"started":"2025-04-24","startedType":"actual","enrolled":390,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06820463/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/"},{"id":"telisotuzumab-adizutecan","kind":"drug","name":"Telisotuzumab adizutecan","route":"/drugs/telisotuzumab-adizutecan/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}